Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2013

Open Access 01-12-2013 | Reviewer acknowledgement

Journal of Hematology & Oncology reviewer acknowledgement 2012

Author: Delong Liu

Published in: Journal of Hematology & Oncology | Issue 1/2013

Login to get access

Contributing reviewers

The editor of Journal of Hematology & Oncology would like to thank all our reviewers who have contributed to the journal in Volume 5 (2012).
Metadata
Title
Journal of Hematology & Oncology reviewer acknowledgement 2012
Author
Delong Liu
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2013
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-6-20

Other articles of this Issue 1/2013

Journal of Hematology & Oncology 1/2013 Go to the issue

Review

Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing

Research

Stem cell factor SALL4, a potential prognostic marker for myelodysplastic syndromes

Research

Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study)

Review

Novel agents for chronic lymphocytic leukemia

Research

Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity

Review

Targeted therapy for HER2 positive breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits